Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MinPAC: Minnelide in Refractory Pancreatic Cancer
NCT03117920Phase 2Completed
- Sponsor
- Minneamrita Therapeutics LLC
- Start
- Apr 2017
- Primary completion
- Jul 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of minnelide in pancreatic cancer (PC), sponsored by Minneamrita Therapeutics LLC. Primary endpoint: Disease Control Rate at 16 weeks. Started Apr 2017; status: completed.
02
Drugs
minnelide
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03117920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117920.